vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and EASTGROUP PROPERTIES INC (EGP). Click either name above to swap in a different company.

Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $190.3M, roughly 1.0× EASTGROUP PROPERTIES INC). EASTGROUP PROPERTIES INC runs the higher net margin — 49.7% vs -14.6%, a 64.3% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 9.1%). EASTGROUP PROPERTIES INC produced more free cash flow last quarter ($126.7M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 9.4%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Genpact Ltd. is an American information technology services, consulting, and outsourcing company headquartered in New York City, New York. Founded in Gurgaon, India, and legally domiciled in Bermuda, Genpact employs more than 125,000 people and provides services to clients in over 30 countries worldwide. Genpact is listed on the NYSE and generated revenues of US$4.48 billion in 2023.

AXSM vs EGP — Head-to-Head

Bigger by revenue
AXSM
AXSM
1.0× larger
AXSM
$196.0M
$190.3M
EGP
Growing faster (revenue YoY)
AXSM
AXSM
+56.0% gap
AXSM
65.0%
9.1%
EGP
Higher net margin
EGP
EGP
64.3% more per $
EGP
49.7%
-14.6%
AXSM
More free cash flow
EGP
EGP
$145.4M more FCF
EGP
$126.7M
$-18.7M
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
9.4%
EGP

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AXSM
AXSM
EGP
EGP
Revenue
$196.0M
$190.3M
Net Profit
$-28.6M
$94.6M
Gross Margin
Operating Margin
-13.8%
Net Margin
-14.6%
49.7%
Revenue YoY
65.0%
9.1%
Net Profit YoY
61.9%
59.2%
EPS (diluted)
$-0.55
$1.77

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
EGP
EGP
Q1 26
$190.3M
Q4 25
$196.0M
$187.5M
Q3 25
$171.0M
$182.1M
Q2 25
$150.0M
$177.3M
Q1 25
$121.5M
$174.4M
Q4 24
$118.8M
$164.0M
Q3 24
$104.8M
$162.9M
Q2 24
$87.2M
$159.1M
Net Profit
AXSM
AXSM
EGP
EGP
Q1 26
$94.6M
Q4 25
$-28.6M
$67.8M
Q3 25
$-47.2M
$67.0M
Q2 25
$-48.0M
$63.3M
Q1 25
$-59.4M
$59.4M
Q4 24
$-74.9M
$58.7M
Q3 24
$-64.6M
$55.2M
Q2 24
$-79.3M
$55.3M
Operating Margin
AXSM
AXSM
EGP
EGP
Q1 26
Q4 25
-13.8%
Q3 25
-27.0%
Q2 25
-24.5%
Q1 25
-46.9%
Q4 24
-61.1%
Q3 24
-59.8%
Q2 24
-89.5%
Net Margin
AXSM
AXSM
EGP
EGP
Q1 26
49.7%
Q4 25
-14.6%
36.1%
Q3 25
-27.6%
36.8%
Q2 25
-32.0%
35.7%
Q1 25
-48.9%
34.1%
Q4 24
-63.1%
35.8%
Q3 24
-61.7%
33.9%
Q2 24
-91.0%
34.8%
EPS (diluted)
AXSM
AXSM
EGP
EGP
Q1 26
$1.77
Q4 25
$-0.55
$1.27
Q3 25
$-0.94
$1.26
Q2 25
$-0.97
$1.20
Q1 25
$-1.22
$1.14
Q4 24
$-1.54
$1.17
Q3 24
$-1.34
$1.13
Q2 24
$-1.67
$1.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
EGP
EGP
Cash + ST InvestmentsLiquidity on hand
$322.9M
$31.4M
Total DebtLower is stronger
$1.6B
Stockholders' EquityBook value
$88.3M
$3.6B
Total Assets
$689.8M
$5.5B
Debt / EquityLower = less leverage
0.45×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
EGP
EGP
Q1 26
$31.4M
Q4 25
$322.9M
$1.0M
Q3 25
$325.3M
$3.0M
Q2 25
$303.0M
$32.9M
Q1 25
$300.9M
$20.5M
Q4 24
$315.4M
$17.5M
Q3 24
$327.3M
$17.0M
Q2 24
$315.7M
$39.4M
Total Debt
AXSM
AXSM
EGP
EGP
Q1 26
$1.6B
Q4 25
Q3 25
$1.4B
Q2 25
$1.5B
Q1 25
$1.5B
Q4 24
$1.5B
Q3 24
$1.6B
Q2 24
$1.7B
Stockholders' Equity
AXSM
AXSM
EGP
EGP
Q1 26
$3.6B
Q4 25
$88.3M
$3.5B
Q3 25
$73.7M
$3.5B
Q2 25
$73.1M
$3.4B
Q1 25
$53.2M
$3.3B
Q4 24
$57.0M
$3.3B
Q3 24
$92.9M
$2.8B
Q2 24
$102.9M
$2.8B
Total Assets
AXSM
AXSM
EGP
EGP
Q1 26
$5.5B
Q4 25
$689.8M
$5.4B
Q3 25
$669.3M
$5.4B
Q2 25
$639.8M
$5.2B
Q1 25
$596.7M
$5.1B
Q4 24
$568.5M
$5.1B
Q3 24
$561.5M
$4.8B
Q2 24
$548.2M
$4.7B
Debt / Equity
AXSM
AXSM
EGP
EGP
Q1 26
0.45×
Q4 25
Q3 25
0.41×
Q2 25
0.43×
Q1 25
0.43×
Q4 24
0.46×
Q3 24
0.57×
Q2 24
0.60×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
EGP
EGP
Operating Cash FlowLast quarter
$-18.7M
$142.3M
Free Cash FlowOCF − Capex
$-18.7M
$126.7M
FCF MarginFCF / Revenue
-9.6%
66.6%
Capex IntensityCapex / Revenue
0.0%
8.2%
Cash ConversionOCF / Net Profit
1.50×
TTM Free Cash FlowTrailing 4 quarters
$-93.9M
$771.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
EGP
EGP
Q1 26
$142.3M
Q4 25
$-18.7M
$480.7M
Q3 25
$1.0M
$138.9M
Q2 25
$-32.4M
$143.4M
Q1 25
$-43.4M
$133.7M
Q4 24
$-26.2M
$416.6M
Q3 24
$-18.6M
$122.9M
Q2 24
$-30.1M
$122.9M
Free Cash Flow
AXSM
AXSM
EGP
EGP
Q1 26
$126.7M
Q4 25
$-18.7M
$404.9M
Q3 25
$988.0K
$120.3M
Q2 25
$-32.4M
$119.2M
Q1 25
$-43.7M
$113.9M
Q4 24
$-26.2M
$357.3M
Q3 24
$-18.7M
$108.5M
Q2 24
$-30.2M
$102.8M
FCF Margin
AXSM
AXSM
EGP
EGP
Q1 26
66.6%
Q4 25
-9.6%
216.0%
Q3 25
0.6%
66.0%
Q2 25
-21.6%
67.2%
Q1 25
-36.0%
65.3%
Q4 24
-22.1%
217.8%
Q3 24
-17.9%
66.6%
Q2 24
-34.6%
64.6%
Capex Intensity
AXSM
AXSM
EGP
EGP
Q1 26
8.2%
Q4 25
0.0%
40.5%
Q3 25
0.0%
10.2%
Q2 25
0.0%
13.7%
Q1 25
0.3%
11.3%
Q4 24
0.0%
36.1%
Q3 24
0.1%
8.9%
Q2 24
0.1%
12.6%
Cash Conversion
AXSM
AXSM
EGP
EGP
Q1 26
1.50×
Q4 25
7.10×
Q3 25
2.07×
Q2 25
2.26×
Q1 25
2.25×
Q4 24
7.10×
Q3 24
2.23×
Q2 24
2.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons